There is conflicting evidence regarding bisphosphonates and atrial fibrillation (AF) risk in osteoporosis patients. However, bisphosphonates are used in much higher doses in treatment of bone metastasis and hypercalcemia, but little is known about the AF risk in cancer patients.
We conducted a nationwide population-based cohort study using Danish databases. All cancer patients exposed to intravenous bisphosphonates during 2000-2008 were matched with two non-exposed cancer patients by cancer type, distant metastasis presence at diagnosis, age, and gender. We used Cox proportional hazard regression to estimate hazards ratios (HRs) of AF/flutter adjusting for important confounding factors.
Of the 3981 cancer patients exposed to intravenous bisphosponates, 128 (3.2%) developed AF/flutter. This condition occurred in 192 (2.4%) of the 7906 non-exposed cancer patients, corresponding to an adjusted HR of 1.7 (95% CI: 1.2-2.4).
Intravenous bisphosphonates may increase AF/flutter risk in cancer patients.
Notes
Cites: BMJ. 2008 Apr 12;336(7648):813-618334527
Cites: N Engl J Med. 2007 Nov 1;357(18):1799-80917878149
Cites: Clin Cancer Res. 2008 Oct 15;14(20):6387-9518927277
Cites: PLoS One. 2009;4(3):e472019266096
Cites: Am J Cardiol. 2009 Mar 15;103(6):824-819268739